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Abstract

Keywords
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Hepatitis C virus (HCV) represents a fundamental issue for public health, with long term
evolution and the gradual appearance of several complications and associated pathologies. One of
these pathologies is represented by cryoglobulinemic vasculitis, a disorder characterized by the
appearance in the patient’s serum of the cryoglobulins, which typically precipitate at temperatures
below normal body temperature (37°C) and dissolve again if the serum is heated. Here, we
describe the case of a patient diagnosed with HCV that, during the evolution of the hepatic
disease, developed a form of cryoglobulinemic vasculitis.
The connection between the vasculitis and the hepatic disorder was revealed following
treatment with interferon, with the temporary remission of both pathologies and subsequent
relapse at the end of the 12 months of treatment, the patient becoming a non-responder. The
particularity of the case is represented by both the severity of the vasculitic disease from its onset
and the deterioration of renal function up to the predialitic phase, a situation not typical of the
evolution of cryoglobulinemia. Taking into account the hepatic disorder, the inevitable evolution
towards cirrhosis, and the risk of developing the hepatocellular carcinoma, close monitoring is
necessary.
 hepatitis C virus, cryoglobulinemic vasculitis, predialitic phase
✓ This case reveals the close connection between the infection with the HCV and the
cryoglobulinemic vasculitis
✓ The particularity is represented by both the existence from the outset of the vasculitic
disease and the current predialitic stage of the patient
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Introduction
Patients with chronic hepatitis C virus (HCV)
infection are at risk for a variety of extrahepatic
manifestations (EHMs). Based on large cohort studies,
up to 70% of patients develop hepatitis C virus
extrahepatic manifestations (1,2). Cryoglobulinemia
represents a pathology based on the presence in the
serum of immunoglobulins (Ig) that precipitate when
the body temperature is lower than 37°C, becoming
soluble again when the body temperature exceeds 37°C
(3). The presence of the cryoglobulins in the serum
determines the development of a syndrome of systemic
inflammation that mainly affects the kidneys and the
skin.
According to the Brouet (4) classification, there are
three types of cryoglobulinemias.
• Type I, or the simple form (10-15%), is
characterized by the presence of a monoclonal Ig (IgM
isotype) in most of cases. It is usually asymptomatic and
is present within the lympho-plasmocitary proliferation
(Waldenström's macroglobulinemia, chronic lymphatic
leukemia, multiple myeloma);
• Type II, or the mixed form (50-60%), is made up of
a monoclonal IgM component that acts as a rheumatoid
factor (RF) and as an antibody against a second
component, a polyclonal IgG isotype component.
Although the second type of cryoglobulinemia has been
considered to be a self-existing pathology (5-6), recent
studies indicate its association with HCV in a proportion
of 40-100, according to the geographical area (7-9).
• Type III is also a mixed form, with immune
complexes made up of two polyclonal Ig (10). The
diagnosis of the mixed cryoglobulinemia syndrome is
based on serologic, pathologic, and clinical criteria.

Case Report
Patient A.A., 59 years old city dweller, was
diagnosed in 2014 with HCV, after the performance of
anti-HCV antibodies. In 2014, the patient underwent
detailed investigations and renal biopsy due to the
increase in liver disease symptomatology and the
occurrence of systemic arterial hypertension,
macroscopic hematuria, leg edemas, and Raynaud
phenomena, being thus diagnosed with renal (chronic
glomerulonephritis), cutaneous, and neurological
cryoglobulinemic vasculitis. In 2015 she was
administered a treatment with Interferon and Ribavirin
for 12 months without a sustained virologic response.
The patient had been diagnosed for several years with
anemia by mixed and renal mechanism and irondeficiency anaemia; for this she has been administered
iron-based medicines and Neorecormon (therapeutically
corrected).

Figure 1. Livedo reticularis hyperpigmentary
lesions at the level of the inferior extremities.
The physical examination revealed the following
aspects: a moderate sclero-tegumentary pallor, with the
presence of certain livedo reticularis hyperpigmentary
lesions and of purpuric lesions around the bilateral leg
surface, gums bleeding, sicca phenomena (xerostomia,
xerophtalmia), respiratory apparatus under normal
limits, arterial tension reaching 140/80 mmHg and the
pulse amounting to 80 beats per minute, the abdomen
sensitive to palpation in the right hypochondrium, the
liver with increased consistency, macroscopic
hematuria, acro-paresthesia.
The paraclinical investigation revealed the
following: thrombocytes 120.000/mm3, erythrocyte
sedimentation rate (ESR) 90 mm/1h, 130 mm/2h, serum
urea 120 mg/dL, creatinine 3.6 mg/dL, eGFR
13mL/min/1.73m2, proteinuria 800.0mg/24h, the Addis
test 2580 erythrocytes/min, aspartataminotranspherasis
(ASAT) 70U/L, alaninaminotranspherasis (ALAT)
59U/L, alkaline phosphatase 67 U/L, gamma-glutamyltranspeptidase (GGT) 162 U/L, total bilirubin 0.48
mg/dL, direct bilirubin 0.15 mg/dL, indirect bilirubin
0.33 mg/dL, cholesterol 170 mg/dL, total protein 6.4
g%, fibrinogen 458 mg/dL, C-reactive protein (CRP)
1.74 mg/L, complement factors such as C3 109.96
mg/dL (n: 90-180 mg/dL), IgA 183.96 mg/dL (n: 70400 mg/dL), IgG 1631.6 mg/dL (n: 700-1600 mg/dL),
IgM 246 mg/dL (n: 40-230 mg/dL); the electrophoresis
of the seric proteins: total protein 6.4 g%,
albumin/globulin 1.25, serum albumin 55.6%, alpha-1
globulin 2.2%, alpha-2 globulin 11.8%, beta-1 globulin
6.2%, beta-2 globulin 3.3%, gama globulin 20.9% with
the tendency to the monoclonal band in the gama
mobility area.
From the abdominal ultrasound we detected a liver
with homogeneous echostructure, with several
infracentimetric calcifications, hepatic left lobe reaching
6.5 cm, hepatic right lobe reaching 15.5 cm, the vena
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porta 8 mm, permeable, hepatopetal flow, both kidneys
reduced in volume (9 cm), normal pancreas and spleen,
normal values of the inferior vena cava, adenopathy
reaching 1.1 cm, situated in the celiac trunk, with no
peritoneal fluid.
Taking into account the long-term evolution of
hepatic disease, a superior digestive endoscopy was
carried out. The endoscopy revealed a stomach with
diffuse hyperemia of the mucous membrane and several
petechiae at the level of the gastric body and bulb with
diffuse hyperemia and several petechiae, without any
esophageal varicose veins, or portal hypertensive
gastropathy.
For a better evaluation of the hepatic status, a real
time sonoelastography (RTE) was carried out, that
emphasized a tessellated structure with the
predominance of the blue areas and a liver fibrosis
index (LFI) of 2.18.

corticotherapy, immunosuppressors, or plasmapheresis

(12).
The primary goal of treatment is HCV eradication,
which is associated with improvement of clinical
symptoms, especially in patients with mixed
cryoglobulinemia (13-16). In patients with severe
symptoms of mixed cryoglobulinemia, treatment with
rituximab may be considered (17). Recent studies have
also tested the combination of PEG-IFN/RBV and
rituximab. The clinical response may be achieved faster
and SVR is not diminished in patients who receive
rituximab (18, 19). Triple therapy was effective in terms
of virologic response as well as clinical response, but
adverse events were frequent (>80% anemia, >50%
infections) (20). Since 2015, IFN-free therapies have
been an option for this group of patients, but so far data
are limited. Recent data show that the INF-free
combination of SOF/ RBV is highly effective in
inducing clinical remission in patients with
cryoglobulinemia vasculitis (78% after 24 weeks of
treatment) in a cohort of 18 patients (21).
Clinical remission was achieved in 50-70% of
patients receiving IFN α plus RBV and was correlated
with a significant reduction of viral concentrations (22).
Despite successful antiviral treatment, cryoglobulinemic
vasculitis may persist in a small collective (23). Recent
data have demonstrated that rituximab is an effective
and safe treatment for advanced liver disease with
mixed cryoglobulinemia (24). Thus, the combination of
Figure 2. RTE reveals the predominance of the
rituximab with PEG-IFN α and ribavirin represents a
blue areas and a LFI of 2.18
therapeutic approach for patients with severe vasculitis
Discussion
from mixed cryoglobulinemia and resistant to antiviral
Cryoglobulinemia induces a systemic vasculitis that therapy alone (25).
mainly affects the small blood vessels and, to a smaller
With its recent introduction, the new interferon-free
extent the medium arteries and veins, through the treatment consists of direct acting antivirals (DAA),
gradual build-up of circulating immune complexes and although the role of rituximab remains to be observed,
the activation of the complement cascade (9). It often as non-response is unusual. The efficacy and safety of
coexists with the HCV infection, being cited as the main treatment with sofosbuvir in HCV-induced MC have
cause of type II mixed cryoglobulinemia (9). Anti-HCV had an SVR12 rate of 83% and has been associated with
antibodies are present, together with an active viral eGFR improvement as well as a reduction in proteinuria
replication,

in

cryoglobulinemia,

most
the

patients

with

cryoprecipitates

mixed (26).

containing

Renal impairment has been observed as an adverse

monoclonal IgM, rheumatoid molecules that mainly act event associated with the use of telaprevir and
against the antigen-antibodies immune complexes (7, 8, boceprevir
11, 12).

(27).

In

patients

with

severe

renal

insufficiency (eGFR <30 ml/min), data for the use of

Cryoglobulinemia manifests at the systemic level, simeprevir, ledipasvir, sofosbuvir, and other direct
affecting the skin, the kidneys, and the nervous system, acting antivirals are emerging. Although the use of
with the severity of the disease varying case by case. sofosbuvir is currently not recommended in patients
Treatment can act either on the viral infection, resorting with eGFR <30 ml/min, safety and efficacy of full dose
in this case to the therapy with interferon, or on sofosbuvir regimen was recently demonstrated in this
thessymptoms,

when

treatment

is

based

on population (28).
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The 3D regimen, comprising of paritaprevir/
ritonavir/ ombitasvir + dasabuvir as well as the NS5A
inhibitor daclatasvir, has been safely administered in
patients with severe renal insufficiency (GFR <30
ml/min) due to the predominant biliary elimination of
these drugs (29). The combination of grazoprevir plus
elbasvir, licensed in 2016, has shown a good safety
profile in patients with serious renal impairment in a
dedicated trial.
A particularity of this case was the large number of
signs and symptoms indicating increased activity of the
autoimmune disease. The prevalence of renal
involvement in the second type of cryoglobulinemia is
variable, from 10 to 60% (4, 6, 30, 31), most often
occurring between the 5th and 6th decades of life, with
a moderate female predominance (32, 33). These
parameters describe our case, as the patient was female
and 59 years old. Although the renal and systemic
manifestations may appear simultaneously, most often
episodes of extra-renal symptomatology with
spontaneous remission are present before the installation
of the renal manifestations (6, 32, 33). The case
described herein belongs to the classical triad described
by Meltzer and Franklin: fatigability, purpura, and
polyarthralgias, as noted in about one third of the cases
(30, 34, 35). While establishing the diagnosis, we noted
a moderate affectation of the nervous system, with faint
acroparesthesias. Other manifestations such as
pulmonary affectation or CNS issues are generally rare
and were excluded in our case. A cardiovascular
investigation was carried out, and although the
cryoglobulinemic vasculitis can determine the
development of pericarditis, valvular pathology,
myocarditis, and congestive cardiac (6, 32), only a
primary arterial hypertension of the second degree was
found, which was therapeutically controlled.
In our case, the patient is a C virus carrier, with
active replication for several years, being subjected to
several investigations for the evaluation of hepatic
function. The prognosis of the hepatic disease is based
on the degree of fibrosis, a proper, complete, and early
evaluation being essential. Although the hepatic biopsy
remains the “gold standard,” a series of noninvasive
techniques concerned with the evaluation of the degree
of fibrosis, including RTE, have recently been recently.
This contemporary and noninvasive method enables
evaluation of the differences of hardness between
affected and healthy tissues, with applicability that
varies from the differentiation of malign tumors from
benign ones via the evaluation of the degree of elasticity
specific to a tumoral tissue, up to the evaluation of the
degree of hepatic fibrosis (36).

The close relation between the infection with HCV
and

the

cryoglobulinemia

is

demonstrated

after

treatment with Interferon for 12 months in 2015 when
an increase in the seric values of RF-IgM, viremy, and
creatinine were noticed, with an amelioration of the
renal function, reaching a eGFR of 13 mL/min/1.73m2
before the initiation of the treatment, a rate of 22
mL/min/1.73m2, at the end of the 12 months; the
cutaneous symptomatology entered remission. The
patient was, however, a non-responder to the therapy
with interferon, which led to another remission at the
end of the treatment, with the recurrence the vasculitic
symptomatology and the increase in the values of the
nitrogen retention.
The status of being a non-responder exposed the
patient to both the progressive deterioration of the
hepatic function, with the gradual installation of
cirrhosis and its complications, and the development of
a hepatocellular carcinoma, which led to the use of
periodical RTE, as this technique can be applied in
either case. By the LFI, the degree of hepatic fibrosis
and potential tumorous formations can be determined.

Conclusions
This case study reveals the close connection
between the infection with the HCV and the
cryoglobulinemic vasculitis with cutaneous, renal, and
neurologic injury, its particularity being represented by
both the existence from the outset of the vasculitic
disease of a large number of signs and symptoms
specific to vasculitis, and the current predialitic stage of
the patient, due to the deterioration of the renal function
during the last years. This pattern is not characteristic of
type II cryoglobulinemia, which in most cases does not
progress towards dialysis, although the affected area is
moderate since the establishment of the diagnosis (6, 35,
36).
Taking into account the failure of the therapy with
interferon and the progressive accentuation of all the
complications, close monitoring of the clinical and
paraclinical state is necessary at periodic time intervals.
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